{"doi":"10.3389/fphar.2020.00784","title":"Surveillance of the Efficacy of Artemisinin–Piperaquine in the Treatment of Uncomplicated Plasmodium falciparum Malaria Among Children Under 5 Years of Age in Est-Mono District, Togo, in 2017","abstract":"Background Malaria is a major public health concern in Togo. The Est-Mono district of Togo has a population of 150,000. Accordingly, the Guangzhou University of Chinese Medicine, China and the Ministry of Health and Social Security, Togo launched a nationwide Mass Drug Administration Project with artemisinin-piperaquine(AP) in Est-Mono. Before launching this project, the sensitivity test of AP was conducted in a general clinic in Elawagnon, Togo. Methods Children aged 6–59 months with uncomplicated falciparum malaria were enrolled in this study. The selected patients were treated with a combination regime of artemisinin–piperaquine. The patients were followed up for 28 days, during which signs of the following were observed for: the duration for fever clearance, parasitemia density, gametophyte generation, cure rate, hemoglobin level, and merozoite surface protein-2 (msp-2) polymorphism. The primary end point was a 28-day cure rate and polymerase chain reaction (PCR)-corrected reinfection and recrudescence. This research followed the standardized World Health Organization (WHO) protocol for the assessment of the efficacy of anti-malarial drugs. Results A total of 91 children with uncomplicated falciparum malaria were enrolled in this study. Adequate clinical and parasitological response (ACPR) before and after PCR-correction were 66 (73%) and 90 (99%), respectively. The average hemoglobin level in the patient increased by 0.05 g/dL per day (p < 0.0001) after the treatment. The gametophyte generation did not decline at the beginning of the treatment; however, after 14 days, it declined (day 21: p < 0.05; day 28: p < 0.01). In the msp-2 polymorphism study of 24 children treated for parasite infection, 1 case of msp-2 with 3D7 haplotype and FC27 haplotype was noted, indicating its recrudescence, with a frequency of 4%. The remaining 23 cases could have been of reinfection, with a frequency of 96%. No serious adverse reactions occurred, and AP was well-tolerated by all patients. Conclusion Artemisinin–piperaquine was found to be an effective combination for treating uncomplicated falciparum malaria in children aged <5 years in Togo, and the drugs were well-tolerated. In Togo, Plasmodium falciparum remains sensitive to artemisinin–piperaquine, necessitating its trial in this region.","journal":"Frontiers in Pharmacology","year":2020,"id":106390,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9466,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":513405,"name":"Zhenyan Zhang","orcid":"0000-0002-9122-2391","position":1,"is_corresponding":false},{"id":514168,"name":"Weisheng Yu","orcid":null,"position":2,"is_corresponding":false},{"id":514169,"name":"Chenguang Lu","orcid":null,"position":3,"is_corresponding":false},{"id":513406,"name":"Guoming Li","orcid":"0000-0002-8289-3310","position":4,"is_corresponding":false},{"id":514170,"name":"Ziyi Pan","orcid":null,"position":5,"is_corresponding":false},{"id":513407,"name":"Hongying Zhang","orcid":"0000-0001-8132-5090","position":6,"is_corresponding":false},{"id":514171,"name":"Wanting Wu","orcid":null,"position":7,"is_corresponding":false},{"id":514172,"name":"Tinah Atcha Oubou","orcid":null,"position":8,"is_corresponding":false},{"id":513408,"name":"Yueming Yuan","orcid":"0009-0005-7443-6098","position":9,"is_corresponding":false},{"id":270399,"name":"Jia–Wen Guo","orcid":"0000-0002-4698-4696","position":10,"is_corresponding":false},{"id":513409,"name":"Yuan Liang","orcid":"0000-0002-6325-8530","position":11,"is_corresponding":false},{"id":513410,"name":"Xinan Huang","orcid":"0000-0003-1628-7416","position":12,"is_corresponding":false},{"id":514173,"name":"Wenfeng Guo","orcid":null,"position":13,"is_corresponding":false},{"id":513411,"name":"Changqing Li","orcid":"0000-0003-4380-2284","position":14,"is_corresponding":false},{"id":514174,"name":"Nadia Julie","orcid":null,"position":15,"is_corresponding":false},{"id":513412,"name":"Qin Xu","orcid":"0000-0002-2146-7342","position":16,"is_corresponding":false},{"id":514175,"name":"Logte Sanwogou","orcid":null,"position":17,"is_corresponding":false},{"id":513413,"name":"Jianping Song","orcid":"0000-0002-5429-0440","position":18,"is_corresponding":false},{"id":513414,"name":"Changsheng Deng","orcid":"0000-0003-3815-3566","position":19,"is_corresponding":false},{"id":513404,"name":"Qi Wang","orcid":"0000-0001-7879-9973","position":0,"is_corresponding":true}],"reference_count":33,"raw_metadata":null,"created_at":"2026-07-18T23:12:27.124515Z","pmid":"32581785","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}